Genovis AB (publ.) (STO:GENO)

Sweden · Delayed Price · Currency is SEK

16.98

-0.02 (-0.12%)

Mar 5, 2026, 10:10 AM CET

-38.03% (1Y)

Market Cap	1.12B
Revenue (ttm)	129.65M
Net Income (ttm)	23.50M
Shares Out	66.06M
EPS (ttm)	0.36
PE Ratio	47.59
Forward PE	38.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,176
Average Volume	106,971
Open	17.06
Previous Close	17.00
Day's Range	16.70 - 17.06
52-Week Range	16.18 - 29.80
Beta	2.12
RSI	33.39
Earnings Date	Feb 12, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 36

Stock Exchange Nasdaq Stockholm

Ticker Symbol GENO

Full Company Profile

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.65 million, a decrease of -1.27% compared to the previous year's 131.32 million. Earnings were 23.50 million, a decrease of -28.61%.

Financial Statements

News

Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect

1 year ago - GuruFocus